Find Motixafortide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Bl-8040, 4f-benzoyl-tn14003, Motixafortide [usan], Tf14016, Bkt140, Bkt 140
Molecular Formula
C97H144FN33O19S2
Molecular Weight
2159.5  g/mol
InChI Key
JJVZSYKFCOBILL-MKMRYRNGSA-N
FDA UNII
DA9G065962

Motixafortide
Motixafortide is an orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. CXCR4 antagonist BL-8040 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor 1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood. The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; SDF-1/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.
1 2D Structure

Motixafortide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-15-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[(4-fluorobenzoyl)amino]pentanoyl]amino]pentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-26-(3-carbamimidamidopropyl)-9,23-bis[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carboxamide
2.1.2 InChI
InChI=1S/C97H144FN33O19S2/c98-60-33-31-58(32-34-60)78(135)119-65(19-8-42-113-93(104)105)79(136)121-68(21-10-44-115-95(108)109)83(140)126-73(51-56-25-30-57-14-1-2-15-59(57)48-56)87(144)130-75-53-152-151-52-74(88(145)118-63(77(101)134)18-7-41-112-92(102)103)129-84(141)69(23-12-46-117-97(111)150)122-81(138)66(20-9-43-114-94(106)107)124-86(143)72(50-55-28-37-62(133)38-29-55)128-90(147)76-24-13-47-131(76)91(148)70(17-4-6-40-100)125-82(139)64(16-3-5-39-99)120-80(137)67(22-11-45-116-96(110)149)123-85(142)71(127-89(75)146)49-54-26-35-61(132)36-27-54/h1-2,14-15,25-38,48,63-76,132-133H,3-13,16-24,39-47,49-53,99-100H2,(H2,101,134)(H,118,145)(H,119,135)(H,120,137)(H,121,136)(H,122,138)(H,123,142)(H,124,143)(H,125,139)(H,126,140)(H,127,146)(H,128,147)(H,129,141)(H,130,144)(H4,102,103,112)(H4,104,105,113)(H4,106,107,114)(H4,108,109,115)(H3,110,116,149)(H3,111,117,150)/t63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-/m0/s1
2.1.3 InChI Key
JJVZSYKFCOBILL-MKMRYRNGSA-N
2.1.4 Canonical SMILES
C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
2.1.5 Isomeric SMILES
C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
2.2 Other Identifiers
2.2.1 UNII
DA9G065962
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Bl-8040

2. 4f-benzoyl-tn14003

3. Motixafortide [usan]

4. Tf14016

5. Bkt140

6. Bkt 140

7. Bkt-140

8. 664334-36-5

9. Da9g065962

10. Tf 14016

11. Tf-14016

12. Motixafortida

13. Motixafortidum

14. Motixafortide [inn]

15. Motixafortide [who-dd]

16. Unii-da9g065962

17. Gtpl10679

18. Chebi:145536

19. 4f-benzoyl-tn-14003

20. Bl8040

21. Who 10935

22. Bl 8040

23. Db14939

24. Q27276305

25. L-argininamide, N2-(4-fluorobenzoyl)-l-arginyl-l-arginyl-3-(2-naphthalenyl)-l-alanyl-l-cysteinyl-l-tyrosyl-n5-(aminocarbonyl)-l-ornithyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-l-arginyl-n5-(aminocarbonyl)-l-ornithyl-l-cysteinyl-, Cyclic (4->13)-disulfide

26. N-(4-fluoro-benzoyl)-l-arginyl-l-arginyl-(l-3-(naphthyl)alanyl)-l-cysteinyl-l-tyrosyl-l-citrullinyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-l-arginyl-l-citrullinyl-l-cysteinyl-l-arginine Amide,cyclic (4-13)-disulfide

27. S3.4,s3.13-cyclo(n.alpha.-(4-fluorobenzoyl)-l-arginyl-l-arginyl-3-(naphthalen-2-yl)-l-alanyl-l-cysteinyl-l-tyrosyl-n5-carbamoyl-l-ornithyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-larginyl-n5-carbamoyl-l-ornithyl-l-cysteinyl-l-argininamide)

2.4 Create Date
2015-09-16
3 Chemical and Physical Properties
Molecular Weight 2159.5 g/mol
Molecular Formula C97H144FN33O19S2
XLogP3-2.9
Hydrogen Bond Donor Count34
Hydrogen Bond Acceptor Count28
Rotatable Bond Count53
Exact Mass2159.0775248 g/mol
Monoisotopic Mass2158.0741700 g/mol
Topological Polar Surface Area943 Ų
Heavy Atom Count152
Formal Charge0
Complexity4500
Isotope Atom Count0
Defined Atom Stereocenter Count14
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Chongqing Sintaho Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Chongqing Sintaho Pharmaceutical
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Exclusivities

read-more
read-more

01

arrow
Medlab Asia & Asia Health
Not Confirmed

BIOLINERX LTD

Israel
arrow
Medlab Asia & Asia Health
Not Confirmed

MOTIXAFORTIDE ACETATE

Exclusivity Code : NCE

Exclusivity Expiration Date : 2028-09-08

Application Number : 217159

Product Number : 1

Exclusivity Details :

blank

02

arrow
Medlab Asia & Asia Health
Not Confirmed

BIOLINERX LTD

Israel
arrow
Medlab Asia & Asia Health
Not Confirmed

MOTIXAFORTIDE ACETATE

Exclusivity Code : ODE-442

Exclusivity Expiration Date : 2030-09-08

Application Number : 217159

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty